Phentolamine bioequivalence study

Detalhes bibliográficos
Autor(a) principal: Silva, L. F.G.
Data de Publicação: 2004
Outros Autores: Moraes, M. O., Santana, G. S.M., Frota Bezerra, F. A., De Nucci, G., Moraes, M. E.A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://hdl.handle.net/11449/219316
Resumo: Objective: To assess the bioequivalence of 2 tablet formulations of phentolamine (Regitine phentolamine 40 mg tablet formulation by Novartis, Brazil, as test formulation, and Vasomax, phentolamine 40 mg tablet formulation by Schering Plough S.A., Brazil, as reference formulation). Methods: A single 40 mg oral dose of each formulation was administered to 36 male healthy volunteers. The study was conducted after screening, using an open, randomized, 2-period crossover design, a 7-day interval between doses, and wash-out period of at least 4 weeks. Plasma samples for determination of phentolamine were obtained predose and at intervals over 720 min postdose. Plasma concentrations were quantified by reversed-phase liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using multiple reactions monitoring (MRM) method. Precision of the method was evaluated using calibration curves and plasma quality control samples. The subjects were monitored throughout the study. Systolic and diastolic blood pressure and pulse rate measurement were taken predose and at intervals up to 720 min. Tolerance of both products was good. No serious adverse reactions were reported. The pharmacokinetic parameters calculated for both compounds included: AUC(0-720 min), AUC(0-∞), Cmax, Cmax/AUC(0-720 min), tmax, t1/2 and kc. Results: The maximum concentrations reached (Cmax) were compared. Regitine 40 mg formulation Cmax geometric mean ratio was 108.29% (90% CI = 98.58 - 118.96) of Vasomax 40 mg formulation. The areas under the curve (AUC(0-720 min)) were compared. Regitine 40 formulation (AUC(0-720 min) geometric mean ratio was 102.33% (90% CI = 97.21 - 107.72) of Vasomax 40 mg formulation. Conclusion: Since the 90% CI for both Cmax and AUC ratio where inside the 80 to 125% interval proposed by the Food and Drug Administration, it is concluded that Regitine 40 mg tablet is bioequivalent to Vasomax for the rate and extent of absorption.
id UNSP_58d00b216b3f6b8b4918cc40fc4a9f8a
oai_identifier_str oai:repositorio.unesp.br:11449/219316
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Phentolamine bioequivalence studyBioavailabilityHumanMass spectrometryPharmacokineticPhentolamineObjective: To assess the bioequivalence of 2 tablet formulations of phentolamine (Regitine phentolamine 40 mg tablet formulation by Novartis, Brazil, as test formulation, and Vasomax, phentolamine 40 mg tablet formulation by Schering Plough S.A., Brazil, as reference formulation). Methods: A single 40 mg oral dose of each formulation was administered to 36 male healthy volunteers. The study was conducted after screening, using an open, randomized, 2-period crossover design, a 7-day interval between doses, and wash-out period of at least 4 weeks. Plasma samples for determination of phentolamine were obtained predose and at intervals over 720 min postdose. Plasma concentrations were quantified by reversed-phase liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using multiple reactions monitoring (MRM) method. Precision of the method was evaluated using calibration curves and plasma quality control samples. The subjects were monitored throughout the study. Systolic and diastolic blood pressure and pulse rate measurement were taken predose and at intervals up to 720 min. Tolerance of both products was good. No serious adverse reactions were reported. The pharmacokinetic parameters calculated for both compounds included: AUC(0-720 min), AUC(0-∞), Cmax, Cmax/AUC(0-720 min), tmax, t1/2 and kc. Results: The maximum concentrations reached (Cmax) were compared. Regitine 40 mg formulation Cmax geometric mean ratio was 108.29% (90% CI = 98.58 - 118.96) of Vasomax 40 mg formulation. The areas under the curve (AUC(0-720 min)) were compared. Regitine 40 formulation (AUC(0-720 min) geometric mean ratio was 102.33% (90% CI = 97.21 - 107.72) of Vasomax 40 mg formulation. Conclusion: Since the 90% CI for both Cmax and AUC ratio where inside the 80 to 125% interval proposed by the Food and Drug Administration, it is concluded that Regitine 40 mg tablet is bioequivalent to Vasomax for the rate and extent of absorption.Department of Urology Clinical Pharmacology Unit UNIFAC Federal University of Ceara, CearaDepartment of Clinical Pharmacology Clinical Pharmacology Unit UNIFAC Federal University of Ceara, CearaClinical Pharmacology State University of Sao Paulo, Sao PauloUnidad de Farmacologia Clinica Departamento de Farmacologia, Rua Cel. Nunes de Melo 1127, Fortaleza-Ceara 60431-970Federal University of CearaUniversidade de São Paulo (USP)Unidad de Farmacologia ClinicaSilva, L. F.G.Moraes, M. O.Santana, G. S.M.Frota Bezerra, F. A.De Nucci, G.Moraes, M. E.A.2022-04-28T18:54:59Z2022-04-28T18:54:59Z2004-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article43-49International Journal of Clinical Pharmacology and Therapeutics, v. 42, n. 1, p. 43-49, 2004.0946-1965http://hdl.handle.net/11449/2193162-s2.0-0347135827Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengInternational Journal of Clinical Pharmacology and Therapeuticsinfo:eu-repo/semantics/openAccess2022-04-28T18:54:59Zoai:repositorio.unesp.br:11449/219316Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462022-04-28T18:54:59Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Phentolamine bioequivalence study
title Phentolamine bioequivalence study
spellingShingle Phentolamine bioequivalence study
Silva, L. F.G.
Bioavailability
Human
Mass spectrometry
Pharmacokinetic
Phentolamine
title_short Phentolamine bioequivalence study
title_full Phentolamine bioequivalence study
title_fullStr Phentolamine bioequivalence study
title_full_unstemmed Phentolamine bioequivalence study
title_sort Phentolamine bioequivalence study
author Silva, L. F.G.
author_facet Silva, L. F.G.
Moraes, M. O.
Santana, G. S.M.
Frota Bezerra, F. A.
De Nucci, G.
Moraes, M. E.A.
author_role author
author2 Moraes, M. O.
Santana, G. S.M.
Frota Bezerra, F. A.
De Nucci, G.
Moraes, M. E.A.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Federal University of Ceara
Universidade de São Paulo (USP)
Unidad de Farmacologia Clinica
dc.contributor.author.fl_str_mv Silva, L. F.G.
Moraes, M. O.
Santana, G. S.M.
Frota Bezerra, F. A.
De Nucci, G.
Moraes, M. E.A.
dc.subject.por.fl_str_mv Bioavailability
Human
Mass spectrometry
Pharmacokinetic
Phentolamine
topic Bioavailability
Human
Mass spectrometry
Pharmacokinetic
Phentolamine
description Objective: To assess the bioequivalence of 2 tablet formulations of phentolamine (Regitine phentolamine 40 mg tablet formulation by Novartis, Brazil, as test formulation, and Vasomax, phentolamine 40 mg tablet formulation by Schering Plough S.A., Brazil, as reference formulation). Methods: A single 40 mg oral dose of each formulation was administered to 36 male healthy volunteers. The study was conducted after screening, using an open, randomized, 2-period crossover design, a 7-day interval between doses, and wash-out period of at least 4 weeks. Plasma samples for determination of phentolamine were obtained predose and at intervals over 720 min postdose. Plasma concentrations were quantified by reversed-phase liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using multiple reactions monitoring (MRM) method. Precision of the method was evaluated using calibration curves and plasma quality control samples. The subjects were monitored throughout the study. Systolic and diastolic blood pressure and pulse rate measurement were taken predose and at intervals up to 720 min. Tolerance of both products was good. No serious adverse reactions were reported. The pharmacokinetic parameters calculated for both compounds included: AUC(0-720 min), AUC(0-∞), Cmax, Cmax/AUC(0-720 min), tmax, t1/2 and kc. Results: The maximum concentrations reached (Cmax) were compared. Regitine 40 mg formulation Cmax geometric mean ratio was 108.29% (90% CI = 98.58 - 118.96) of Vasomax 40 mg formulation. The areas under the curve (AUC(0-720 min)) were compared. Regitine 40 formulation (AUC(0-720 min) geometric mean ratio was 102.33% (90% CI = 97.21 - 107.72) of Vasomax 40 mg formulation. Conclusion: Since the 90% CI for both Cmax and AUC ratio where inside the 80 to 125% interval proposed by the Food and Drug Administration, it is concluded that Regitine 40 mg tablet is bioequivalent to Vasomax for the rate and extent of absorption.
publishDate 2004
dc.date.none.fl_str_mv 2004-01-01
2022-04-28T18:54:59Z
2022-04-28T18:54:59Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv International Journal of Clinical Pharmacology and Therapeutics, v. 42, n. 1, p. 43-49, 2004.
0946-1965
http://hdl.handle.net/11449/219316
2-s2.0-0347135827
identifier_str_mv International Journal of Clinical Pharmacology and Therapeutics, v. 42, n. 1, p. 43-49, 2004.
0946-1965
2-s2.0-0347135827
url http://hdl.handle.net/11449/219316
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv International Journal of Clinical Pharmacology and Therapeutics
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 43-49
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799964803390767104